Highlights of the Annual Dialysis Conference: Chronic Kidney Disease Related-Anemia

February 18-20, 2007; Denver, Colorado

Anne G. Le, PharmD, RPh


April 02, 2007

In This Article

Novel Agents for the Treatment of Anemia of Chronic Kidney Disease

Epoetin or darbepoetin alfa have suggested dosing regimens of 2-3 times/week to once every 1-2 weeks, but methoxy polyethylene glycol-epoetin beta, a novel ESA currently under development for the treatment of anemia in patients with CKD, may allow for extension of the dosing interval while providing maintenance hemoglobin levels. Methoxy polyethylene glycol-epoetin beta is chemically synthesized and is different from erythropoietin by switching the bonds between the amino groups and methoxy polyethylene glycol-succinimidyl butanoic acid. This novel agent has been designed to have reduced receptor affinity and decreased receptor mediated elimination. In clinical trials, methoxy polyethylene glycol-epoetin beta has a serum half-life of 133 ± 9.83 hours (IV) and 137 ± 21.9 hours (SC) and its pharmacokinetics support a different interaction with the epoetin receptor. Because of this long half-life, dosing at extended intervals (every 4 weeks, or once a month) may be possible. In contrast, the in vivo serum half-life of epoetin beta is approximately 8 hours. What follows are summarizations of key data that were presented on methoxy polyethylene glycol-epoetin beta and other issues surrounding anemia management in patients with CKD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.